Lomerizine Prophylaxis for Pediatric Migraine: Efficacy and Predictors of Treatment Response-A Retrospective Cohort Study.

Lomerizine is a medication used to prevent migraines, particularly in children. This study looked at 83 patients aged 18 and younger who received lomerizine. Researchers wanted to see how effective it was in reducing headache days. They defined success as a 50% decrease in headaches each month. At 3-4 months, 42.5% of patients showed improvement. By 6-8 months, that number increased to 50.7%. The study also examined factors that might predict who would respond well to treatment. These included psychosocial factors and certain medical conditions. The findings suggest that lomerizine can be an effective option for children with migraines. However, not all patients responded the same way. Understanding which factors help predict treatment success can guide better care for young migraine sufferers. Clinical relevance: This study indicates that lomerizine may effectively reduce migraine frequency in children, highlighting the need for personalized treatment approaches.